Featured Research

from universities, journals, and other organizations

Leukemia drug shows promise for skin, breast and other cancers

Date:
August 19, 2014
Source:
Loyola University Health System
Summary:
A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers. Dasatinib fights leukemia by checking the uncontrolled growth of cancer cells. But when used against other cancer cells, researchers found, the drug employs a different strategy: It causes the cells to clump together, thus preventing them from migrating. Without the ability to migrate, cancer cells cannot metastasize (spread to other parts of the body).

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine.

Dasatinib fights leukemia by checking the uncontrolled growth of cancer cells. But when used against other cancer cells, researchers found, the drug employs a different strategy: It causes the cells to clump together, thus preventing them from migrating. Without the ability to migrate, cancer cells cannot metastasize (spread to other parts of the body).

Mitchell Denning, PhD, and colleagues discovered the molecular mechanism behind this cell-cell adhesion. The researchers reported their findings in a study published online ahead of print in the journal Molecular Carcinogenesis.

Dasatinib (trade name, Sprycel) is approved for certain types of leukemia. It targets a protein called BCR-ABL that fuels the growth of cancer cells.

BCR-ABL is similar to a protein called Fyn that's found in other malignancies, including breast, brain, pancreatic, skin and head-and-neck cancers. Fyn is associated with cell-cell adhesion and cell migration.

Denning and colleagues found that applying dasatinib to cancer cells in the laboratory caused the cells to clump together, and also prevented the cells from migrating. They found similar results with breast cancer cells. While dasatinib did not eliminate Fyn, it inhibited the protein's activity.

The researchers also found that dasatinib reduced the number and size of tumors in mice that had skin cancer.

Denning noted that clinical trials are underway to test dasatinib on patients with melanoma, prostate cancer, pancreatic cancer, endometrial cancer, gastrointestinal stromal cancer, ovarian cancer, multiple myeloma, Hodgkin's lymphoma and acute lymphoblastic leukemia.

"We think dasatinib can be applied to many different types of cancer," Denning said.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sarah E. Fenton, Kelli A. Hutchens, Mitchell F. Denning. Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion. Molecular Carcinogenesis, 2014;

Cite This Page:

Loyola University Health System. "Leukemia drug shows promise for skin, breast and other cancers." ScienceDaily. ScienceDaily, 19 August 2014. <www.sciencedaily.com/releases/2014/08/140819094007.htm>.
Loyola University Health System. (2014, August 19). Leukemia drug shows promise for skin, breast and other cancers. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2014/08/140819094007.htm
Loyola University Health System. "Leukemia drug shows promise for skin, breast and other cancers." ScienceDaily. www.sciencedaily.com/releases/2014/08/140819094007.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins